日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Complementary dual-virus strategy drives synthetic target and cognate T-cell engager expression for endogenous-antigen agnostic immunotherapy

互补的双病毒策略驱动合成靶标和同源T细胞衔接器表达,用于不依赖于内源性抗原的免疫疗法。

Zaid Taha # ,Mathieu Joseph François Crupi # ,Nouf Alluqmani ,Duncan MacKenzie ,Sydney Vallati ,Jack Timothy Whelan ,Faiha Fareez ,Akram Alwithenani ,Julia Petryk ,Andrew Chen ,Marcus Mathew Spinelli ,Kristy Ng ,Judy Sobh ,Christiano Tanese de Souza ,Priya Rose Bharadwa ,Timothy Kit Hin Lee ,Dylan Anthony Thomas ,Ben Zhen Huang ,Omar Kassas ,Joanna Poutou ,Victoria Heather Gilchrist ,Stephen Boulton ,Max Thomson ,Ricardo Marius ,Mohsen Hooshyar ,Scott McComb ,Rozanne Arulanandam ,Carolina Solange Ilkow ,John Cameron Bell ,Jean-Simon Diallo

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSVΔ51 oncolytic virotherapy

Pevonedistat 是一种首创的 NEDD8 激活酶抑制剂,可增强癌细胞对 VSVΔ51 溶瘤病毒疗法的敏感性。

Boaz Wong,Anabel Bergeron,Glib Maznyi,Kristy Ng,Anna Jirovec,Harsimrat K Birdi,Daniel Serrano,Marcus Spinelli,Max Thomson,Zaid Taha,Akram Alwithenani,Andrew Chen,Ian Lorimer,Barbara Vanderhyden,Rozanne Arulanandam,Jean-Simon Diallo

Syngeneic mouse model of human HER2+ metastatic breast cancer for the evaluation of trastuzumab emtansine combined with oncolytic rhabdovirus

用于评估曲妥珠单抗-美坦新联合溶瘤弹状病毒治疗的人类HER2+转移性乳腺癌同源小鼠模型

Zaid Taha ,Mathieu J F Crupi ,Nouf Alluqmani ,Faiha Fareez ,Kristy Ng ,Judy Sobh ,Emily Lee ,Andrew Chen ,Max Thomson ,Marcus M Spinelli ,Carolina S Ilkow ,John C Bell ,Rozanne Arulanandam ,Jean-Simon Diallo

Unlocking the potential of dimethyl fumarate: enhancing oncolytic HSV-1 efficacy for wider cancer applications

释放富马酸二甲酯的潜力:增强溶瘤性 HSV-1 的疗效,以应用于更广泛的癌症治疗

Akram Alwithenani ,Zaid Taha ,Max Thomson ,Andrew Chen ,Boaz Wong ,Rozanne Arulanandam ,Jean-Simon Diallo